Notice to Participate in RFA-AA-17-013 "Model Continuums of Care Initiative (MCCI) for Women and Girls at Risk and Living With HIV/AIDS and Harmful Alcohol and Associated Comorbidities Planning Cooperative Agreement (U34)"

Notice Number: NOT-DA-16-042

Key Dates
Release Date: October 17, 2016

Related Announcements
RFA-AA-17-013    

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

This Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate in the Funding Opportunity Announcement (FOA) RFA-AA-17-013 "Model Continuums of Care Initiative (MCCI) for Women and Girls at Risk and Living With HIV/AIDS and Harmful Alcohol and Associated Comorbidities Planning Cooperative Agreement (U34)".

The following sections have been updated to reflect the participation of NIDA in this FOA.

Part 1. Overview Information
Components of Participating Organizations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.273, 93.279

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

Specific Areas of Research Interest
Appropriate topics to be addressed by new and continuing research on women and girls at risk and living with co-occurring HIV/AIDS, problem alcohol and other substance use, and associated comorbidities include but are not limited to those listed below:

Prevention and Treatment Research

  • Identifying the alcohol and other drug (AOD) screening and treatment strategies that are most effective in reducing AOD-related disparities in HIV incidence and treatment outcomes among women and girls.  In particular, identifying the best approaches to integrating alcohol screening, brief intervention, and referral to treatment (SBIRT) into community outreach efforts to increase HIV testing and linkage to treatment.  Identifying best approaches to integrating effective interventions for harmful drinking and other substance use into HIV treatment to improve retention in care and other clinical outcomes.
  • Examining the impact of harmful drinking and associated comorbidities and of HIV-related knowledge, attitudes, beliefs, and other social and psychological factors on women and girls’ acceptance of microbicide and antiretroviral therapies, including pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), across a range of formulations and delivery systems.  Identifying best approaches to integrating alcohol interventions into PrEP and PEP for women and girls.
  • Determining how integrated HIV/alcohol interventions may be adapted to reduce trauma against women and girls and to mitigate trauma-related effects on HIV transmission and on HIV/AIDS and AOD treatment outcomes.
  • Identifying and addressing potential gender-related differences in the impact of alcohol and other substances on the immunologic response to HIV therapy and/or on treatment adherence.
  • Identifying the most effective strategies for reducing the impact of alcohol on mother to child transmission (MTCT) and best approaches to bringing them to population scale, particularly in resource-limited settings.
  • Determining how environmental, venue, or contextual/setting factors beyond the actual treatment administered (e.g., social supports, stigma, employment status, housing status, food security, incarceration, etc.) moderate the outcomes of interventions for HIV/AIDS and alcohol use among women and girls across the lifespan.  What interventions could be put in place to mitigate the impact of structural factors associated with negative clinical outcomes and to amplify the impact of factors associated with improved outcomes?

NIDA is soliciting applications that promote the development and evaluation of integrated multilevel interventions to reduce substance abuse consumption as a key approach to preventing new infections and enhancing treatment adherence in communities in the U.S.  Furthermore, NIDA is especially interested in studies that address nicotine and marijuana use among women and girls at risk and living with HIV, including pregnant women. 

Current Language

Section II. Award Information

Funds Available and Anticipated Number of Awards
NIAAA intends to commit an estimated total of $900K Total Costs per year over 3 years to fund approximately 2-3 U34 awards, corresponding to a total of up to $300K in Total Costs per year per award over 3 years.

New Language

Section II. Award Information

Funds Available and Anticipated Number of Awards
NIAAA intends to commit an estimated total of $900K Total Costs per year over 3 years to fund approximately 2-3 U34 awards, corresponding to a total of up to $300K in Total Costs per year per award over 3 years.  NIDA intends to commit $500K.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Dionne Jones, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email:  djones1@nida.nih.gov

Financial/Grants Management Contact(s)

Suezette Epps
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-6702
Email: eppss@mail.nih.gov

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to: